PATENT CLAIM ANALYSIS

Application Number: 16080752
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "649000"]

Abstract:
This invention relates to methods of treating a patient with ovarian cancer having deficiencies in homologous recombination (HR) comprising administering to the patient (i) an effective amount of ganetespib, or a pharmaceutically acceptable salt thereof; and (ii) an effective amount of a DNA-damaging or repair-inhibiting agent.

Claim (Index 10):
The method of any one of  claims 1 - 8 , wherein the DNA-damaging or repair-inhibiting agent is a topoisomerase I inhibitor, and the topoisomerase I inhibitor is irinotecan, topotecan, camptothecin, or lamellarin D.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.34146
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14772549', '14307708', '15433249', '14466208', '15192497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7244578933396418
- 35 USC 102 Novelty (BERT): 0.5340520693312568
- Combined Prediction Score: 0.7054173109388033
- Mean Citation Score: 303.0549180000001
- Max Citation Score: 330.02466
- Similarity Product: 219.8834115662384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test